S 707106

Drug Profile

S 707106

Alternative Names: S-707106

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Shionogi
  • Class Antihyperglycaemics; Insulin sensitisers
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 23 Jul 2015 Phase-IIa is ongoing for Type-2 diabetes mellitus in USA
  • 09 May 2013 S 707106 is still in phase IIa development for Type-2 diabetes mellitus in USA
  • 12 Jan 2012 Shionogi completes a phase IIa trial in Type-2 diabetes mellitus in USA (NCT01240759)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top